Mendus AB (publ) (IMMUS.XC)

1.7960 -0.0040 (-0.22%) At close: 11:40AM BST

Mendus AB (publ)

VAestra TrAedgArdsgatan 15
Stockholm 111 53
Sweden
46 87 32 84 00
https://www.mendus.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 27

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Erik Manting Ph.D.	Chief Executive Officer	N/A	N/A	1971
Mr. Alex Karlsson-Parra M.D., Ph.D.	Co-Founder & Chief Scientific Officer	1.42M	N/A	1950
Ms. Lotta Ferm	Chief Financial Officer	N/A	N/A	1966
Dr. Leopold Bertea Ph.D.	Chief Technology Officer	N/A	N/A	1965
Dr. Sven M. Rohmann M.D., MBA, Ph.D.	Business Development Advisor	N/A	N/A	1962
Dr. Jeroen Rovers M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1971

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company's products also develops ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase II clinical trial to treat gastrointestinal stromal tumors. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai, as well as a collaboration with the Australasian Leukaemia and Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Corporate governance

Mendus AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.